Navigation Links
Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma
Date:12/14/2011

ffort. This landmark 1000-patient longitudinal study will provide unprecedented insights into the molecular course of a patient's disease, from initial diagnosis through their response to treatment. As consortium members, Onyx and other industry partners will have early access to the data that emerge from this study, potentially providing them with new targets for intervention and biomarker development, accelerating the time from discovery to clinical development.

"There is a significant need for new treatment options in multiple myeloma, and we are proud to work in partnership with MMRF, researchers and others in the industry to better understand the disease at a molecular level and potentially develop targeted therapies that will improve the lives of these patients," said N. Anthony Coles, M.D., president and CEO, Onyx. "We share the MMRF's vision that to succeed we will not only need great science, but also the creation of innovative models for collaboration to accelerate rapid development of promising treatments."

About Multiple Myeloma

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.(i)

About the Multiple Myeloma Research Foundation (MMRF)

Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $170 million
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Multiple Myeloma Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014 ... industry leader in bioactive lipid-targeted therapeutics, received official notification ... has been granted another key patent supporting its ... newly issued patent, European patent No. 2087002, claims ... substance in Lpath,s two lead compounds, iSONEP and ...
(Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Nov. 16 Announced on November 06, 2009 by Mr. ... Inc., and the Board of MEGGLE Group of Wasserburg, Germany, ... Mr. Christian Sedlatschek, CFO, the companies are entering a long-term ... States. , DAVISCO Foods is an international cheese and food ...
... , ACPCN Joins Congressional Leaders to Introduce Legislation ... Association of Community Pharmacists Congressional Network (ACPCN) will join ... Real Medication Access Cost Savings Act." The bill ... dependence on pharmacy benefit management (PBM) companies for medications. ...
Cached Medicine Technology:DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose. 2Pharmacists Work with Congress to Address PBM Abuses 2
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... , - New Hayfever Relief Product ... on the Internet , - With Photo ... years ago, however, it,s believed that,it now affects as many as ... suffer,with hayfever, it,s either complete misery with symptoms such as reduced,concentration, ...
... likely than men to feel the pinch of rising ... (52%) of working-age women reporting problems accessing needed care ... a new Commonwealth Fund study finds. Women who are ... percent of underinsured women have problems accessing care because ...
... single protein prevents early damage in blood vessels from ... to research published online today in the journal ... signaling protein called cyclophilin A (CypA) from a strain ... against abdominal aortic aneurysm (AAA). , The aorta ...
... state man had underlying health problems, officials say , , ... in his 30s from Snohomish County, Wash., is the third ... state health officials said late Saturday. , In a Department ... an underlying heart condition, died last week with what appear ...
... to Support the Nancy Davis Foundation for Multiple Sclerosis ... of the world,s most exclusive super sport cars, donated ... Spyder to support the Nancy Davis Foundation for Multiple ... MS charity event at the Hyatt Regency Century Plaza ...
... alcohol are more likely to choose quick rewards , , ... a risk factor for alcoholism, a new study finds. ... bred to crave large amounts of alcohol were more ... The rodents, impulsivity was tested by giving them the ...
Cached Medicine News:Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 2Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 3Health News:7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems 2Health News:7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems 3Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 2Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 3Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 4Health News:Third U.S. Swine Flu Death Reported 2Health News:Third U.S. Swine Flu Death Reported 3Health News:Third U.S. Swine Flu Death Reported 4Health News:Third U.S. Swine Flu Death Reported 5Health News:Third U.S. Swine Flu Death Reported 6Health News:Third U.S. Swine Flu Death Reported 7Health News:Third U.S. Swine Flu Death Reported 8Health News:Third U.S. Swine Flu Death Reported 9Health News:Third U.S. Swine Flu Death Reported 10Health News:Third U.S. Swine Flu Death Reported 11Health News:First U.S. Lamborghini Gallardo LP 560-4 Spyder Auctioned at Race to Erase MS Charity Event 2Health News:Impulsivity Raises Alcoholism Risk 2
... The CA-1000 counts a Petri dish ... on the optical characteristics of the colonies ... The CA-1000 is equipped with three types ... are lighter or darker than the agar ...
Basic critical care testing. Measures pH, pCO2, and pO2 from 85 L whole-blood sample....
... Rapidpoint 400 is a sophisticated whole blood ... point-of-care testing while also satisfying the stringent ... multiple-use measurement cartridge contains all of the ... long-lasting cartridge includes the sampling unit, all ...
The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
Medicine Products: